Harrys A Torres1, Jeff Hosry1, Parag Mahale1, Minas P Economides1, Ying Jiang1, Anna S Lok2. 1. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Abstract
Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been reported in retrospective studies. We sought to determine prospectively the incidence, predictors, and clinical significance of HCV reactivation during cancer treatment. HCV-infected patients receiving cancer treatment at our institution between November 2012 and July 2016 were studied. Reactivation was defined as an increase in HCV-RNA ≥1 log10 IU/mL over baseline and hepatitis flare as an increase in alanine aminotransferase to ≥3 times the upper limit of normal. One hundred patients were studied, 50 with hematologic malignancies and 50 with solid tumors. Reactivation occurred in 23 (23%) patients, including 18 (36%) patients with hematologic malignancies and 5 (10%) patients with solid tumors. In univariate analysis, patients with reactivation were more likely than those without reactivation to have prolonged lymphopenia (median, 95 versus 22 days; P = 0.01) and to have received rituximab (44% versus 9%; P < 0.0001), bendamustine (22% versus 0%; P < 0.001), high-dose steroids (57% versus 21%; P = 0.001), or purine analogs (22% versus 5%; P = 0.02). Rituximab (odds ratio = 9.52; P = 0.001), and high-dose steroids (odds ratio = 5.05; P = 0.01) retained significance in multivariable analysis. Of the 23 patients with reactivation, 10 (43%) had hepatitis flare. No patient with reactivation experienced liver failure or liver-related death within 36 weeks after initiation of cancer treatment. Fourteen patients with hepatitis flare, six of whom had reactivation, required discontinuation or dose reduction of cancer treatment. CONCLUSION: HCV reactivation occurred in 23% of HCV-infected patients receiving cancer treatment, and most had an unremarkable clinical course. However, reactivation can affect the cancer treatment plan. Our findings suggest that HCV infection should not contraindicate cancer therapy and infected patients should have access to multiple cancer treatments with close monitoring while receiving regimens associated with HCV reactivation. (Hepatology 2018;67:36-47).
Hepatitis C virus (HCV) reactivation in patients receiving cancer treatment has been reported in retrospective studies. We sought to determine prospectively the incidence, predictors, and clinical significance of HCV reactivation during cancer treatment. HCV-infectedpatients receiving cancer treatment at our institution between November 2012 and July 2016 were studied. Reactivation was defined as an increase in HCV-RNA ≥1 log10 IU/mL over baseline and hepatitis flare as an increase in alanine aminotransferase to ≥3 times the upper limit of normal. One hundred patients were studied, 50 with hematologic malignancies and 50 with solid tumors. Reactivation occurred in 23 (23%) patients, including 18 (36%) patients with hematologic malignancies and 5 (10%) patients with solid tumors. In univariate analysis, patients with reactivation were more likely than those without reactivation to have prolonged lymphopenia (median, 95 versus 22 days; P = 0.01) and to have received rituximab (44% versus 9%; P < 0.0001), bendamustine (22% versus 0%; P < 0.001), high-dose steroids (57% versus 21%; P = 0.001), or purine analogs (22% versus 5%; P = 0.02). Rituximab (odds ratio = 9.52; P = 0.001), and high-dose steroids (odds ratio = 5.05; P = 0.01) retained significance in multivariable analysis. Of the 23 patients with reactivation, 10 (43%) had hepatitis flare. No patient with reactivation experienced liver failure or liver-related death within 36 weeks after initiation of cancer treatment. Fourteen patients with hepatitis flare, six of whom had reactivation, required discontinuation or dose reduction of cancer treatment. CONCLUSION:HCV reactivation occurred in 23% of HCV-infectedpatients receiving cancer treatment, and most had an unremarkable clinical course. However, reactivation can affect the cancer treatment plan. Our findings suggest that HCV infection should not contraindicate cancer therapy and infectedpatients should have access to multiple cancer treatments with close monitoring while receiving regimens associated with HCV reactivation. (Hepatology 2018;67:36-47).
Authors: Harrys A Torres; Pearlie P Chong; Marcos De Lima; Mark S Friedman; Sergio Giralt; Sarah P Hammond; Patrick J Kiel; Henry Masur; George B McDonald; John R Wingard; Maya Gambarin-Gelwan Journal: Biol Blood Marrow Transplant Date: 2015-08-06 Impact factor: 5.742
Authors: M P Economides; P Mahale; A Kyvernitakis; F Turturro; H Kantarjian; A Naing; J Hosry; T L Shigle; A Kaseb; H A Torres Journal: Aliment Pharmacol Ther Date: 2016-10-11 Impact factor: 8.171
Authors: M Schirmer; W Vogel; J Thaler; K Grünewald; F Umlauft; F Geisen; U Zilian; G Konwalinka Journal: Lancet Date: 1994-06-04 Impact factor: 79.321
Authors: Parag Mahale; Dimitrios P Kontoyiannis; Roy F Chemaly; Ying Jiang; Jessica P Hwang; Marta Davila; Harrys A Torres Journal: J Hepatol Date: 2012-08-04 Impact factor: 25.083
Authors: H M Diepolder; R Zachoval; R M Hoffmann; E A Wierenga; T Santantonio; M C Jung; D Eichenlaub; G R Pape Journal: Lancet Date: 1995-10-14 Impact factor: 79.321
Authors: Scott D Ramsey; Joseph M Unger; Laurence H Baker; Richard F Little; Rohit Loomba; Jessica P Hwang; Rashmi Chugh; Monica A Konerman; Kathryn Arnold; Alex R Menter; Eva Thomas; Ross M Michels; Carla Walker Jorgensen; Gary V Burton; Nishin A Bhadkamkar; Dawn L Hershman Journal: JAMA Oncol Date: 2019-04-01 Impact factor: 31.777
Authors: Harrys A Torres; Anna S Lok; Maria E Suarez-Almazor; Carla L Warneke; Ahmed Kaseb; Ethan Miller; Erich M Sturgis; Jessica T Foreman; Georgios Angelidakis; Sairah Ahmed; Alessandra Ferrajoli; Felipe Samaniego; Ernest T Hawk; Jessica P Hwang Journal: Support Care Cancer Date: 2020-04-20 Impact factor: 3.603
Authors: Parag Mahale; Chinenye Ugoji; Eric A Engels; Meredith S Shiels; Sally Peprah; Lindsay M Morton Journal: AIDS Date: 2020-07-01 Impact factor: 4.632